Stay updated on Lenvatinib Combo With Pembrolizumab in Endometrial Cancer Clinical Trial
Sign up to get notified when there's something new on the Lenvatinib Combo With Pembrolizumab in Endometrial Cancer Clinical Trial page.

Latest updates to the Lenvatinib Combo With Pembrolizumab in Endometrial Cancer Clinical Trial page
- Check2 days agoNo Change Detected
- Check9 days agoChange DetectedThe page shows a minor version update from Revision: v3.4.1 to Revision: v3.4.2; no study data or visible content were changed. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.0%

- Check17 days agoChange DetectedRevision updated from v3.4.0 to v3.4.1 on the page. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.0%

- Check31 days agoChange DetectedThe page now includes a glossary display option and a new QC metadata label 'Last Update Submitted that Met QC Criteria' along with a 'No FEAR Act Data' notice. The revision footer shows 'Revision: v3.4.0', replacing the previous 'v3.3.4'.SummaryDifference0.1%

- Check38 days agoChange DetectedThe page shows an internal revision label updated from v3.3.3 to v3.3.4, which does not affect the study information or user-facing content. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.0%

- Check67 days agoChange DetectedLocations have been expanded and reorganized to include numerous sites across the United States and internationally. Several regional location groupings were removed, and the revision label now shows v3.3.3.SummaryDifference2%

- Check89 days agoChange DetectedSite revision updated to v3.3.2; the previous revision v3.3.1 has been removed.SummaryDifference0.0%

Stay in the know with updates to Lenvatinib Combo With Pembrolizumab in Endometrial Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Lenvatinib Combo With Pembrolizumab in Endometrial Cancer Clinical Trial page.